bluuebunny/crossref_metadata_2025_split huggingface dataset:
Feminization in hepatocellular carcinoma corrected by chemotherapy: A case report
Authors: Aabo Kristian , Dimitrov Nikolay V. 
Published: February 2007

AbstractA 17‐year‐old boy with metastatic hepatocellular carcinoma and feminization became asymptomatic after administration of antineoplastic agents. Serum estradiol level, urine estrogens, and tumor estrogen receptors were changed after the treatment. Achievement of partial remission resulted in normalization of the serum sex hormone profile and disappearance of the feminization in spite of the presence of residual tumor. Thus, serum hormone levels alone can‐not be used as tumor markers for control of therapy. This suggests that chemotherapy may have altered the biological behavior of the tumor, which resulted in loss of its ability to synthesize estrogen and estrogen receptors.
Metastasis to the central nervous system from colorectal cancer
Authors: Chyun Y. , Hayward E. , Lokich J. 
Published: February 2007

AbstractEighteen of 78 patients (23%) with metastatic colorectal cancer developed clinically significant metastases to the central nervous system (CNS). The patients developing CNS metastases had a decreased likelihood of associated liver metastases compared to the patients without CNS metastases (22% versus 80%). Pulmonary metastases were present in 55% of patients with CNS lesions and in 25% of those without CNS lesions. Overall survival from diagnosis of the primary tumor was comparable (median, 28 months) for patients with or without CNS lesions. The incidence of CNS metastases was comparable irrespective of Duke stage at presentation. For early lesions (Duke B or C), CNS metastases were associated with a shorter survival (31 versus 42 months). For advanced disease (Duke D lesions) at presentation, the overall survival of the group with CNS metastases was longer (24 versus nine months). Therefore, the longer survivorship of patients with advanced disease may contribute to a greater likelihood of CNS metastases.
DOPA Metabolism in Neuroblastoma
Authors: Helson L. , Johnson G. A. , Smith R. 
Published: February 2007

AbstractBlood plasma samples from 60 neuroblastoma patients prior to, during, and following treatment were studied for their content of circulating DOPA using a radioenzymatic assay. Normal values were established from children who were tumor‐free or had other nonneurogenic tumors. The highest plasma DOPA concentration in tumor‐free or nonneuroblastoma controls was 5.3 ng/ml with a mean of 2.15 ng/ml. Most neuroblastoma patients (28/31) with active disease had DOPA values above this level. Only one out of 30 “successfully” treated patients without evidence of disease was encountered with an abnormally high level. In treated patients, elevated values forewarned of impending clinical recurrence or persistent tumor. Cerebrospinal fluid DOPA levels in one patient with cerebral neuroblastoma were extraordinarily high and suggests that this assay may prove useful to distinguish neuroblastoma from other central neuroectodermal or metastatic tumors.Plasma DOPA appears to be a reliable predictive and diagnostic test for neuroblastoma.
Beta‐2‐microglobulin review: Its relevance in clinical oncology
Authors: Cooper E. H. , Plesner T. 
Published: February 2007

AbstractBeta‐2‐microglobulin (β2‐m) is an intrinsic part of the HLA system and is most probably involved in cell recognition. The levels of free β2‐m in the blood and urine are influenced by β2‐m production and its clearance and destruction in the kidney. Many tumors can be associated with an elevated serumβ2‐m, the reason is unknown. The most promising application of β2‐m as a tumor marker would appear to be lymphoid malignancies, especially multiple myeloma and chronic lymphocytic leukemia.
Hypoglycemia in a child with hepatoblastoma
Authors: Ha K. , Ikeda T. , Okada S. , Inui K. , Tagawa T. , Takada K. , Uchimura N. , Kakudo K. , Okada A. , Yabuuchi H. 
Published: February 2007

AbstractA five‐year‐old boy with hepatoblastoma, who showed a severe hypoglycemia as an initial symptom, was studied. After resection of tumors, hypoglycemia disappeared and did not recur despite recurrence of tumor. A high concentration of insulin‐like activity (ILA) was found in preoperative serum and in the tumor extract. Hypoglycemia in this patient seemed to depend mainly on ILA and in part on liver enzyme activities related to carbohydrate metabolism.
Osteogenic sarcoma following treatment with megavoltage radiation and chemotherapy for bone tumors in children
Authors: Freeman Carolyn R. , Gledhill Robert , Chevalier Louise M. , Whitehead V. Michael , Esseltine D. L. 
Published: February 2007

AbstractWhile osteogenic sarcoma has been well‐recognized as a late complication of exposure to high doses of ionizing radiation in the orthovoltage energy range, it has been less frequently reported in patients treated with megavoltage radiation. This potential complication should, however, not be dismissed as an occurrence to be seen only after high‐dose orthovoltage radiation. We have recently seen two children who developed osteogenic sarcoma following treatment with megavoltage radiation and combination chemotherapy for primary bone tumors. The implications in regard to aggressive multimodality treatment for pediatric malignancies are discussed.
The nude mouse model for human retinoblastoma: A system for evaluation of retinoblastoma therapy
Authors: Benedict William F. , Dawson Jo Ann , Banerjee Ashutosh , Murphree A. Linn 
Published: February 2007

AbstractWe have critically examined the nude mouse model for human retinoblastoma to determine whether or not characteristics found in the parent tumor are retained in the mouse. We have demonstrated that most tumors grown in the anterior chamber of the nude mouse maintain a similar karyotype, show the same degree of differentiation and develop an adequate tumor blood supply when compared to the primary tumor from which they were obtained. Because of these findings, we suggest that this model may be particularly useful for evaluating new methods or combinations of treatment for human retinobastoma.
Doxorubicin, vincristine, and cis‐diamminedichloroplatinum (II) therapy in patients with advanced breast cancer
Authors: Trump Donald L. , Ettinger David S. , Abeloff Martin D. 
Published: February 2007

AbstractPreliminary data suggesting synergistic activity of cisplatinum and doxorubicin and the expected poor prognosis of women with breast cancer who progress on treatment with cyclophosphamide, methotrexate and 5‐fluorouracil (CMF), led to a trial of monthly doxorubicin (50 mg/M2), vincristine (1.4 mg/M2) and cisplatinum (50 mg/M2) in such patients. Overall partial response rate to this regimen was 42%; 37% progressed and 21% could not complete two cycles of therapy because of gastrointestinal (three or renal (one) toxicity. This study does not support the use of cisplatinum, 50 mg/M2, in combination with doxorubicin and vincristine in patients with breast cancer which has proven refractory to CMF therapy.
Protected environments in cancer chemotherapy: Design and function of a large unit
Authors: Bodey Gerald P. , Rosenbaum Beverly 
Published: February 2007

AbstractThe construction of a new hospital building permitted the design of a new protected environment unit. The design and operating procedures of this unit are described. Microbiological monitoring has been conducted using air sampling, floor sampling, and settling plates. Microbial contamination is substantially lower in the protected environment unit than in comparable locations elsewhere in the hospital.
Interstitial pneumonitis associated with mitomycin C and DTIC: A case report
Authors: Yoon J. M. , Rao U. , Vassilopoulos P. P. , Ledesma E. , Mittelman A. 
Published: February 2007

AbstractA case of interstitial pneumonitis secondary to mitomycin C and DTIC combination therapy in a 58‐year‐old male with metastatic adenocarcinoma of the rectum is reported. Dry cough and dyspnea, especially on exertion, were presenting symptoms. Arterial blood gas analysis was compatible with severe impairment in pulmonary diffusion capacity. Chest x‐ray showed a diffuse increase in interstitial markings in both lung fields consistent with interstitial pneumonia. Histologically, prominence of type I pneumocytes, focal proliferation of type II pneumocytes, and varying degree of fibroblastic proliferation and collagenization within the alveolar septae were observed. The obliteration of alveolar septal vessels due to endothelial edema and/or proliferation of fibroblast‐like mesenchymal cells were also noted. Withdrawal of drugs and institution of high dose corticosteroid therapy were followed in rapid improvement in dyspnea and arterial blood gas findings. If diagnosed early, this potentially life threatening complication may respond to such therapy.
Acute myeloblastic leukemia following non‐hodgkin lymphoma in an adolescent. A report of a case with preleukemic syndrome, and review of the literature
Authors: Kaur Prakash , Miller Denis R. , Andreeff Michael , Chaganti Raju , Meyers Paul A. 
Published: February 2007

AbstractReports of acute nonlymphoblastic leukemia occurring after successful treatment of Hodgkin and non‐Hodgkin lymphoma (NHL) are appearing with increasing frequency. Two years after completion of LSA2‐L2 therapy for stage III, poorly differentiated lymphocytic lymphoma, a 16‐year‐old boy developed a preleukemic state characterized by a refractory macrocytic anemia with excess blasts, dyshematopoiesis, abnormal cluster:colony ratio on in vitro bone marrow culture, and acquired deficiencies of erythrocyte pyruvate kinase, triose phosphate isomerase, and adenylate kinase. Four months later acute myeloblastic leukemia was evident. The RNA index determined by flow cytofluorometry was increased. Four marker chromosomes were found and involved complex translocation of chromosomes 11 and 17 (t11;17) in 100% of the cells, and chromosome 4 (t4q;4) in 10% of the cells.A thorough literature search uncovered four other reports of acute nonlymphoblastic leukemia occurring in children treated for NHL and a total of 58 cases in the adult and pediatric age groups. Over 50% of the patients had AML, were men over 50 years of age, and were treated with radiotherapy and chemotherapy. It is anticipated that additional cases of second malignancies will be reported in this population of patients whose outlook for the curability of the primary malignancy is 75%.
CT scans of long‐term survivors of various childhood malignancies
Authors: Allen Jeffrey C. , Deck Michael D. F. , Howieson John , Brown Mark 
Published: February 2007

AbstractForty‐two children with various systemic malignancies in continuous remission for 1 to 3 years after the completion of chemotherapy had CT scans with normal ventricular dimensions, similar to a noncancer “control” population. Seventeen of these patients had acute lymphocytic leukemia (ALL) treated either with prophylactic cranial irradiation and intrathecal methotrexate [7] or intrathecal methotrexate alone [10] and the remaining 25 patients had soft tissue sarcomas. Sixteen other patients with sarcomatous meningitis had enlarged ventricles while on chemotherapy. Nine had ALL. Seven had soft tissue sarcomas, none of whom received any prior CNS irradiation or intrathecal chemotherapy. In this retrospective study no evidence of hydrocephalus or significant white matter hypodensity was detected in long‐term survivors of childhood cancer, regardless of whether prophylactic intrathecal chemotherapy and/or cranial irradiation was given. Direct involvement of the CNS with meningeal cancer was the most important association with ventriculomegaly.
The role of local radiation in the treatment of non‐hodgkin lymphoma in children
Authors: Jereb Berta , Wollner Norma , Kosloff Cynthia , Exelby Philip 
Published: February 2007

AbstractEighty‐one patients between 1 and 15 years of age with non‐Hodgkin lymphoma were seen at Memorial Sloan‐Kettering Cancer Center (MSKCC) in an 8‐year period ending December 1973. There was no statistically significant difference among the survival distributions for site or histologic type. The patients also were divided into three groups according to the chemotherapeutic regimen employed in their care, and further subdivided as to whether they received “curative” radiotherapeutic attempts. Children treated with multiple agent chemotherapeutic regimen (LSA‐2) did significantly better than children of the LSA‐1 or nonprotocol (NP) group. Children with Stage I and Stage II disease did significantly better than children with Stage III and Stage IV disease. Radiation therapy as employed in this study prevented recurrence of local disease. All patients in whom the disease recurred died within a year from the appearance of recurrence. However, no statistically significant association between radiation and survival could be shown in this series.
Methyl‐CCNU, 6‐Thioguanine, and 5‐fluorouracil in advanced colorectal cancer
Authors: Aroney R. S. , Dalley D. N. , Chan W. K. , Bell D. R. , Levi J. A. 
Published: February 2007

AbstractConsecutive studies were undertaken in advanced colorectal adenocarcinoma, comparing two different schedules of the combination methyl‐CCNU, 6‐thioguanine, and 5‐fluorouracil in 89 patients. The two schedules exhibited similar efficacies, with a combined complete and partial remission rate of 17%, a median response duration of 36+ weeks, and a median survival of 53+ weeks. Significant symptomatic benefit was seen in 52% of patients. Toxicity was predominantly hemopoietic and gastrointestinal, being acceptable overall, with only minor qualitative differences between the two protocols. These tripledrug regimens exhibit response rates and survival patterns comparable with those reported for other multidrug combinations and some single agents. It would appear that major improvements in the management of advanced‐stage disease must await the availability of more efficacious agents used alone or in combination.
A prospective study of histocompatible leukocyte and platelet transfusions during induction chemotherapy of adult acute nonlymphocytic leukemia
Authors: Cooper M. Robert , Heise Eugene R. , Ii Frederick Richards , Muss Hyman B. , White Douglas R. , Rhyne Leonard , Howard Virginia , Spurr Charles L. 
Published: February 2007

AbstractA prospective clinical trial was conducted to test the effectiveness of granulocyte transfusions during induction chemotherapy of patients with adult acute nonlymphocyte leukemia. Thirty‐eight patients who received prophylactic granulocyte transfusions from related donors when their phagocyte counts decreased to < 1000 μl were compared to twenty‐five controls who did not have qualified donors from which to obtain granulocyte transfusions. The frequency of complete remissions (CR) (28/38 versus 7/25) was significantly greater for the granulocyte transfusion group than for controls. Patients older than 45 responded more often in the transfused group (P < 0.025) when compared to the similar age group in controls. Both duration of complete remission and survival were greater in the granulocyte transfused group. However, these differences were not statistically significant. Survival for all responders (complete plus partial remission) was longer for the granulocyte transfusion group (P = 0.01). No significant difference in frequency or severity of either infection or hemorrhage was noted in the two groups. The advantage noted in this study largely occurred in patients older than 45 and this suggests that this age group is more likely to respond if they have histocompatible donors from which to obtain granulocyte and platelet transfusions. Immune mechanisms may be involved in the beneficial effects observed with HLA compatible granulocyte transfusions.
VP 16–213 and cyclophosphamide in the treatment of refractory acute nonlymphocytic leukemia with monocytic features
Authors: Hurd David D. , Peterson Bruce A. , McKenna Robert W. , Bloomfield Clara D. 
Published: February 2007

AbstractThe treatment of refractory acute nonlymphocytic leukemia remains a major clinical problem in leukemia therapy. VP 16–213 is an investigational agent that may have specificity for monocytic blasts, and the combination of VP 16–213 and cyclophosphamide is synergistic in experimental leukemia. Seven patients with highly refractory acute nonlymphocytic leukemia, which demonstrated monocytic features, were treated with a combination of VP 16–213 and cyclophosphamide after they had failed to respond to multiple courses of intensive induction regimens. Three complete remissions and one partial remission were achieved. The times to complete remission were 21, 23, and 34 days. The durations of complete remission were 5, 9, and 12+ months. Myelo‐suppression was the most common side effect; one patient experienced nausea and stomatitis. There were no documented infections or hemorrhage, and no one died as a result of therapy. This combination is both well tolerated and effective in the treatment of refractory leukemia with monocytic features.
Sick sinus syndrome with seroconstrictive pericarditis in malignant lymphoma involving the heart: A case report
Authors: Donnelly M. Sheila , Weinberg David S. , Skarin Arthur T. , Levine Harold D. 
Published: February 2007

AbstractA case of the sick sinus syndrome and constrictive pericarditis with effusion (seroconstrictive pericarditis) as manifestations of lymphomatous involvement of the heart is presented. Autopsy findings documented infiltration of the sinus node by undifferentiated malignant lymphoma cells. The clinical course is described and problems with diagnosis and management of such a complication are discussed. This is one of the few cases in the literature in which an uncommon cause of conduction system disease and pericardial constriction was substantiated by electrocardiogram, angiography, and autopsy.
Lung abscesses following corticosteroid therapy for central nervous system metastases
Authors: Joss Rudolf A. , Goldberg Ronald S. , Yates Jerome W. , Krakoff Irwin H. 
Published: February 2007

AbstractAlthough the occurrence of lung abscesses has decreased among the general population since the advent of antibiotics, a specific subgroup of cancer patients has demonstrated a propensity for this complication. Four patients with lung cancer, receiving corticosteroid therapy for brain metastases, developed large lung abscesses. These patients represent 12% of the 33 patients with central nervous system metastases seen in this institution over the period of one year. Physicians should be alert to this possible complication of corticosteroid therapy in patients with lung cancer.
Progress in the treatment of childhood acute leukemia: A review
Authors: Steinhorn Sandra C. , Myers Max H. 
Published: February 2007

AbstractThe dramatic improvements in the survival experience for children diagnosed with acute leukemia are analyzed using data collected through hospitals participating in the National Cancer Institute's End Results Group Program between 1950 and 1973. Children under 15 years of age who were diagnosed with both acute lymphocytic leukemia (ALL) and acute nonlymphocytic leukemia (ANLL) showed moderate improvements in the 1950s, but beginning in the 1960s those with ALL did far better. Statistically significant differences at the 0.05 level were noted between their three‐year survival rates for all cohorts analyzed between 1960 and 1973. For the 1970‐1973 cohort, three‐year survival rates were 49% and 20% for ALL and ANLL, respectively, and five‐year survival rates were 34% and 12%. Between 1950 and 1976 the age‐adjusted incidence rate for all childhood leukemias remained relatively stable in a sample of five geographic areas, changing from 4.6 per 100,000 children under 15 years of age to 4.3 per 100,000. In contrast, the corresponding age‐adjusted mortality rate fell approximately 45% over the same period, from 4.4 per 100,000 to 2.4 per 100,000.
Treatment of a primary intracranial germ cell tumor with systemic chemotherapy
Authors: Kirshner Jeffrey J. , Ginsberg Sandra J. , Fitzpatrick Alicia V. , Comis Robert L. 
Published: February 2007

AbstractPrimary germ cell neoplasms of the central nervous system (CNS) are rare tumors which generally respond to radiotherapy. Experience is limited in managing the refractory patient. We report a patient whose suprasellar dysgerminoma responded completely to 5,000 rad. Seven years later, disease recurrence was refractory to an additional 4,000 rad. Theorizing that the “blood‐brain barrier” was no longer intact after extensive radiotherapy and tumor involvement of the ventricular system, the patient was treated with systemic bleomycin, cisplatin, and vinblastine. Pharmacokinetic studies revealed that the bleomycin and cisplatin entered the cerebrospinal fluid. Serial CT scans and CSF levels of β‐HCG confirmed the clinical impression of a partial remission. Subsequent tumor progression was refractory to therapy with intraventricular bleomycin. It is concluded that systemic chemotherapy may be beneficial in certain cases of CNS germ cell neoplasms.
Malignant mesothelioma in children: Report of seven cases and review of the literature
Authors: Brenner Joseph , Sordillo Peter P. , Magill Gordon B. 
Published: February 2007

AbstractSeven children with malignant mesothelioma have been seen at Memorial Hospital since 1953. In six, the origin was at the pleura and in one at the peritoneum. None of the patients related a history of exposure to asbestos. Two patients lived more than five years. The other five patients died within two years of the diagnosis. Distant metastases were seen in four of the patients, including three who had metastases to brain. Surgery or radiotherapy were not effective in controlling the disease in most of the patients. One patient had a complete response to a combination of Adriamycin, cyclophosphamide, and vincristine and has remained free of disease for 51/2 years. The seven cases are reviewed, as are the other 42 cases of malignant mesothelioma in children reported in the literature.
Characteristics of children with acute nonlymphocytic leukemia in long‐term continuous remission: A report for childrens cancer study group
Authors: Baehner Robert L. , Kennedy Anne , Sather Harland , Chard Ronald L. , Hammond Denman 
Published: February 2007

AbstractChildren and young adults less than 18 years of age with acute nonlymphocytic leukemia who remained in long term bone marrow and extramedullary remission for two years or longer since starting maintenance were compared to the remaining responders for the following characteristics: cell type, sex, age at diagnosis, race, pretreatment, white blood count, length of time from start of induction therapy to achievement of an M1 marrow, marrow rating at day 56 of therapy, marrow rating at the start of maintenance therapy, and specific study. Forty‐eight patients of a group of 333 qualified as having long term remission (14.4%). Multivariant analysis indicated that patients between the ages of 3 and 10 years (p = 0.003) as well as the length of time to achieve an M1 marrow from the start of treatment (p = 0.03) were the only characteristics associated with achievement of a long term remission. Maintenance therapy was discontinued in 15 patients from 2.5 to 4.8 years after start of maintenance and all patients remained in bone marrow remission for periods from 0+ to 3.0+ years after stopping treatment. Of the 33 who have remained on a continuous maintenance therapy 12 have had bone marrow relapses. These data confirm the prognostic value of age and length of time to achieve remission during induction in acute nonlymphocytic leukemia and suggest that there may be no significant benefit from maintenance therapy continued beyond 2 years for patients in their initial remission.